2 hours ago
2
MarketBeat
Wed, March 11, 2026 astatine 12:01 PM CDT 8 min read
-
YCANTH commercialized momentum: Revenue grew >130% successful 2025 with Q4 nett YCANTH gross of $3.7 million, dispensed applicator units astir doubled to 51,196 for the year, and inventory is "normalized" aft co-pay/access initiatives and the YcanthRx pharmacy launch.
-
Pipeline and planetary expansion: Verrica has initiated a planetary signifier III programme for YCANTH successful communal warts with Torii (first diligent dosed Dec 2025 and Torii backing astir costs) and is readying 2 placebo‑controlled signifier III studies for VP‑315 aft beardown signifier II signals (97% ORR); an EU submission for YCANTH whitethorn hap wrong 12 months and YCANTH launched successful Japan.
-
Balance expanse strengthened: The institution completed a $50 million PIPE, utilized proceeds to discontinue indebtedness (including a $35 cardinal OrbiMed settlement), ended 2025 with $30.1 million successful currency and expects backing into 2027 contempt a full‑year GAAP nett nonaccomplishment of $17.9 million.
-
Interested successful Verrica Pharmaceuticals Inc.? Here are 5 stocks we similar better.
Verrica Pharmaceuticals (NASDAQ:VRCA) utilized its 4th fourth and year-end 2025 firm update telephone to item what absorption described arsenic a “fundamental” concern translation driven by sharper commercialized execution, pipeline progress, and a strengthened equilibrium sheet.
President and CEO Jayson Rieger said the institution focused successful 2025 connected establishing YCANTH arsenic a “new modular of care” for molluscum contagiosum by stabilizing the commercialized enactment and investing successful diligent access. He reported YCANTH gross grew by much than 130% successful 2025 versus 2024, portion selling, wide and administrative (SG&A) expenses declined by much than 40% year-over-year implicit the aforesaid period.
→ Microsoft Positioned to Win AI Race With Dual-Model Strategy
Rieger said YCANTH nett gross was $3.7 million successful the 4th fourth of 2025, up 3.2% sequentially from the 3rd quarter, with demand-driven purchases continuing. He besides emphasized that inventory levels were “normalized” for the 4th consecutive quarter, with shipments to distributors intimately tracking underlying demand.
Dispensed applicator units—a metric the institution uses to picture demand—were 13,654 successful Q4 2025, up 58% from Q4 2024 but down astir 3% from Q3 2025. Rieger attributed immoderate of the sequential softness to commercialized execution factors and aboriginal said January 2026 was apt affected by important wintertime upwind connected the East Coast. He noted that February dispensed applicator units per selling time rebounded to a grounds monthly precocious since launch.
English (CA) · 
English (US) · 
Spanish (MX) ·